Dishman Carbogen Amcis Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2025 ,inter alia, to consider and approve the Un-Audited Financial ....

Revenue declinedProfit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

DCAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹291.10

prior close

₹294.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+0.5% vs market

Pharmaceuticals peers, median of 153sector-0.4%+0.6% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+2.3

15m

+2.4

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-0.3+0.5-0.4+0.6

Next day

+0.3+0.7-0.4+0.1+0.2

+2.2-0.0+2.3-0.4+2.6

-8.0-1.7-6.3-1.5-6.5

-14.5-1.3-13.2-1.6-12.9

-14.1-1.7-12.4-2.5-11.7

-12.0-1.1-10.9-1.9-10.1

15d

-21.3-4.0-17.3-3.8-17.5

-18.6-3.3-15.2-3.6-15.0

-15.0-5.5-9.4-5.4-9.6

-25.4-12.0-13.4-11.1-14.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dishman Carbogen Amcis has informed the stock exchanges that its Board of Directors will meet on 4th November 2025 to consider and approve the Un-Audited Financial Results for the quarter and half year ended 30th September 2025 (Q2 FY26). The company also confirmed that the trading window for dealing in securities was closed from 1st October to 6th November 2025 for directors, designated persons, and their immediate relatives. The trading window will reopen on 7th November 2025. This is a standard regulatory intimation under SEBI Listing Regulations 29 and 50, with no financial figures disclosed at this stage.

Likely market impact

No direct impact on shareholders yet — this is a routine pre-results announcement. Investors should watch for the actual Q2/H1 FY26 numbers on or after 4th November 2025, which will be the next catalyst for the stock.

By the numbersConsolidated · Q2 FY26 vs Q2 FY25

	Q2 FY26	Q2 FY25	Change
Revenue	₹652.7 Cr	₹789.0 Cr	−17.3%
Operating profit	₹22.43 Cr	₹38.43 Cr	−41.6%
Profit after tax	₹65.27 Cr	₹33.09 Cr	+97.2%
EBITDA margin	22.8%	18.3%	+4.5 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.